Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01317472 · ClinicalTrials.gov registry record · NA
The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux
A NA study, sponsored by Indiana University.
- Terminated
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT01317472 is a NA study that was terminated before completion, run by Indiana University. The registered enrollment target is 11 participants.
The verdict
NCT01317472, a NA study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
Recent studies have demonstrated that patients with throat-related reflux often require twice daily proton pump inhibitor therapy to attain significant symptomatic improvement, with once daily therapy offering little relief. As dexlansoprazole is a twice-daily release proton pump inhibitor requiring only once-daily dosing, it may provide laryngopharyngeal reflux (LPR) symptomatic relief comparable to that of twice daily dosing, yet be more readily approved by third party payers because of its once daily dosing requirements. It is hypothesized that, in patients with pharyngeal-probe proven throat reflux, there will be significantly greater improvement in symptoms and pharyngeal probe findings in those patients receiving dexlansoprazole than those receiving placebo alone.
Interventions
- DRUG Placebo
- DRUG dexlansoprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-03 |
| Est. Completion | 2013-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01317472
The ClinicalTrials.gov registry entry for NCT01317472 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01317472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01317472 about?
NCT01317472 is a clinical study titled "The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux". Recent studies have demonstrated that patients with throat-related reflux often require twice daily proton pump inhibitor therapy to attain significant symptomatic improvement, with once daily therapy offering little relief. As dexlansoprazole is a twice-daily release proton pump inhibitor requiring...
What is the current status of trial NCT01317472?
This trial is currently terminated. It is a NA study. The enrollment target is 11 participants. The study started on 2011-03. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01317472?
The interventions under investigation include: Placebo (DRUG), dexlansoprazole (DRUG).
Who is sponsoring clinical trial NCT01317472?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.